A New Alternative Drug With Fewer Adverse Effects in the Treatment of Sydenham Chorea: @entity4677 Efficacy in a XXXX .

@entity1 @entity4677 @entity1767 @entity29279
UNASSIGNED: @entity4677 ( @entity29279 ) efficacy in the treatment of chorea in Huntington disease, paroxysmal nonkinesigenic dyskinesia, paroxysmal kinesigenic choreoathetosis, and dyskinetic cerebral palsy was reported in some studies. We described a case of a @entity1 with Sydenham chorea treated with @entity29279 . A 7.5-year-old male @entity1 presented with chorea, orofacial dyskinesia, speech impairment, and irritability. Echocardiographic examination revealed mitral insufficiency. Sydenham chorea was diagnosed after excluding other diseases causing chorea. Although his choreiform movements were decreased substantially with @entity1767 treatment, speech impairment, orofacial dyskinesia, and light chorea were continued. Therefore, on day 9, @entity29279 was added, and his complaints resolved in a few days. The severity of the chorea according to the Universidade Federal de Minas Gerais Sydenham's Chorea Rating Scale decreased from 47 to 5 points after @entity29279 treatment. Thus, on day 13, the dose of @entity1767 was reduced and gradually discontinued within 4 days. Symptoms did not reoccur. The follow-up at 1.5 months revealed recurrence of complaints due to discontinuation of @entity29279 by parents. Signs and symptoms were regressed completely within 1 week after @entity29279 retreatment. We suggest that @entity29279 with fewer adverse effects comparing to other drugs may be considered to be a good alternative in the treatment of Sydenham chorea.
